NASDAQ:NKTX

Nkarta News Headlines

$25.03
-0.13 (-0.52 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.24
▼
$25.41
50-Day Range
$23.94
▼
$36.68
52-Week Range
$22.46
▼
$79.16
Volume196,298 shs
Average Volume199,118 shs
Market Capitalization$821.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Nkarta (NASDAQ NKTX) News Headlines Today

SourceHeadline
Nkarta (NASDAQ:NKTX) Stock Price Down 3.2%Nkarta (NASDAQ:NKTX) Stock Price Down 3.2%
americanbankingnews.com - June 8 at 12:56 PM
How Much Will the Nkarta Deal Help CRISPR Therapeutics?How Much Will the Nkarta Deal Help CRISPR Therapeutics?
finance.yahoo.com - June 6 at 3:02 PM
Nkarta, Inc. (NASDAQ:NKTX) Insider Ralph Brandenberger Sells 4,140 SharesNkarta, Inc. (NASDAQ:NKTX) Insider Ralph Brandenberger Sells 4,140 Shares
americanbankingnews.com - June 4 at 6:06 PM
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Rating of "Buy" from AnalystsNkarta, Inc. (NASDAQ:NKTX) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - May 31 at 5:30 AM
Comparing Bellicum Pharmaceuticals (NASDAQ:BLCM) and Nkarta (NASDAQ:NKTX)Comparing Bellicum Pharmaceuticals (NASDAQ:BLCM) and Nkarta (NASDAQ:NKTX)
americanbankingnews.com - May 30 at 3:06 PM
Nkarta (NASDAQ:NKTX) Trading Down 5.7%Nkarta (NASDAQ:NKTX) Trading Down 5.7%
americanbankingnews.com - May 25 at 3:16 PM
Nkarta Announces June 2021 Investor Conference ScheduleNkarta Announces June 2021 Investor Conference Schedule
finance.yahoo.com - May 25 at 8:51 AM
Nkarta (NASDAQ:NKTX) Trading Down 7.6%Nkarta (NASDAQ:NKTX) Trading Down 7.6%
americanbankingnews.com - May 19 at 3:40 PM
Crispr Therapeutics Ag (CRSP-Q) Quote - Press Release - The Globe and MailCrispr Therapeutics Ag (CRSP-Q) Quote - Press Release - The Globe and Mail
theglobeandmail.com - May 14 at 7:25 AM
Nkarta Reports First Quarter 2021 Financial Results and Business ProgressNkarta Reports First Quarter 2021 Financial Results and Business Progress
finance.yahoo.com - May 14 at 7:25 AM
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for CancerCRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
finance.yahoo.com - May 6 at 4:42 PM
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell MalignanciesNkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
finance.yahoo.com - April 28 at 10:31 AM
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business ProgressNkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
finance.yahoo.com - March 25 at 8:27 PM
Nkarta Announces February and March 2021 Investor Conference ScheduleNkarta Announces February and March 2021 Investor Conference Schedule
finance.yahoo.com - February 17 at 7:01 PM
Heres how much money was made on Bay Area IPOs in 2020, with insiders doing bestHere's how much money was made on Bay Area IPOs in 2020, with insiders doing best
bizjournals.com - January 5 at 9:34 AM
Is NKTX A Good Stock To Buy Now?Is NKTX A Good Stock To Buy Now?
finance.yahoo.com - December 9 at 4:02 PM
Fate Stock Soars After Novel Natural-Killer Treatment for Cancers Makes a SplashFate Stock Soars After Novel Natural-Killer Treatment for Cancers Makes a Splash
finance.yahoo.com - December 7 at 4:33 PM
Nkarta EPS misses by $0.05Nkarta EPS misses by $0.05
seekingalpha.com - November 12 at 7:41 PM
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
finance.yahoo.com - November 12 at 7:41 PM
Nkarta Reports Third Quarter 2020 Financial ResultsNkarta Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 12 at 7:41 PM
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of CancerNkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
finance.yahoo.com - November 9 at 10:32 AM
Nkarta Announces November & December 2020 Investor Conference ScheduleNkarta Announces November & December 2020 Investor Conference Schedule
finance.yahoo.com - November 5 at 6:59 PM
How Many Nkarta, Inc. (NASDAQ:NKTX) Shares Do Institutions Own?How Many Nkarta, Inc. (NASDAQ:NKTX) Shares Do Institutions Own?
finance.yahoo.com - October 23 at 7:52 AM
Nkarta names new CFONkarta names new CFO
seekingalpha.com - October 6 at 2:26 PM
Nkarta Announces October 2020 Investor Conference ScheduleNkarta Announces October 2020 Investor Conference Schedule
markets.businessinsider.com - September 29 at 9:34 AM
Nkarta Announces September 2020 Virtual Investor Conference ScheduleNkarta Announces September 2020 Virtual Investor Conference Schedule
finance.yahoo.com - September 8 at 4:21 PM
Nkarta EPS of -$30.06Nkarta EPS of -$30.06
seekingalpha.com - August 20 at 6:29 PM
Nkarta Reports Second Quarter 2020 Financial ResultsNkarta Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 20 at 6:29 PM
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters Option to Purchase AdditionalNkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional
www.bloomberg.com - August 1 at 7:35 PM
Nkarta Inc.Nkarta Inc.
www.marketwatch.com - August 1 at 7:35 PM
Nkarta, Inc. Common Stock (NKTX)Nkarta, Inc. Common Stock (NKTX)
www.nasdaq.com - August 1 at 7:35 PM
Nkarta PRICESNkarta PRICES
markets.businessinsider.com - July 26 at 5:47 PM
Nkarta, Inc. (NKTX)Nkarta, Inc. (NKTX)
seekingalpha.com - July 26 at 5:47 PM
RA Capital discloses 17.2% stake in NkartaRA Capital discloses 17.2% stake in Nkarta
seekingalpha.com - July 24 at 11:34 PM
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesNkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - July 17 at 8:43 AM
Nkarta raises nearly $290 million in IPONkarta raises nearly $290 million in IPO
finance.yahoo.com - July 17 at 8:43 AM
Biopharmaceutical Company Nkarta Raises $290M In IPOBiopharmaceutical Company Nkarta Raises $290M In IPO
feeds.benzinga.com - July 15 at 6:15 AM
This page was last updated on 6/13/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.